Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction

Zheng, Lan; Shen, Xing; Wang, Ying; Li, Wei; Yu, Zhengquan; Tang, Xuemei; Yuan, Chan-Xing; Cui, Yun; Li, Jun; Xiang, Xiao

doi:10.3736/jcim20040405

Cited by 2 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall risk of bias was identified high in sixteen studies ( Meng et al, 2020 ; Yang et al, 2021 ; Liu et al, 2020 ; Han, 2020 ; Ren et al, 2018 ; Luo and Liu, 2016 ; Xu et al, 2014 ; Mo, 2010 ; Li, 2021 ; Liu, 2020 ; Wang, 2020 ; Xu et al, 2019 ; Huang et al, 2019b ; Huang et al, 2019a ; Huang, 2019 ; Liu, 2018 ), moderate in seven studies ( Liu and Liu, 2005 ; Liu and Yuan, 2021 ; Chen et al, 2020 ; Liu, 2015 ; Liu, 2014 ; Liu, 2013 ; Cheng et al, 2012 ) and low in eleven studies ( Liu, 2019 ; Jiang et al, 2018 ; Ma and Zhou, 2020 ; You, 2019 ; Wang et al, 2018 ; Wang et al, 2021b ; Song, 2018 ; Feng et al, 2017 ; Ma and Lin, 2016 ; Tan et al, 2016 ; Zhuo et al, 2016 ), as is shown in Figure 2 and Supplementary Figure S1 . The randomization process was considered some concerns as thirteen studies ( Liu and Liu, 2005 ; Cheng et al, 2012 ; Liu, 2013 ; Liu, 2014 ; Xu et al, 2014 ; Liu, 2015 ; Luo and Liu, 2016 ; Xu et al, 2019 ; Chen et al, 2020 ; Liu, 2020 ; Liu et al, 2020 ; Li, 2021 ; Liu and Yuan, 2021 ) did not provide enough information in the method of random sequence generation.…”

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 98%

“…In October 2021, we supplemented the retrieval of four studies that met the inclusion criteria. Finally, 34 studies ( Liu and Liu, 2005 ; Mo, 2010 ; Cheng et al, 2012 ; Liu, 2013 ; Liu, 2014 ; Xu et al, 2014 ; Liu, 2015 ; Luo and Liu, 2016 ; Ma and Lin, 2016 ; Tan et al, 2016 ; Zhuo et al, 2016 ; Feng et al, 2017 ; Jiang et al, 2018 ; Liu, 2018 ; Ren et al, 2018 ; Song, 2018 ; Wang et al, 2018 ; Huang et al, 2019a ; Huang et al, 2019b ; Huang, 2019 ; Liu, 2019 ; Xu et al, 2019 ; You, 2019 ; Wang, 2020b ; Chen et al, 2020 ; Han, 2020 ; Liu, 2020 ; Liu et al, 2020 ; Ma and Zhou, 2020 ; Meng et al, 2020 ; Wang et al, 2021b ; Li, 2021 ; Liu and Yuan, 2021 ; Yang et al, 2021 ) were included. The screening process is summarized in the flow diagram in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Subgroup analysis was carried out to examine differences in therapy duration. Ten studies ( Liu and Liu, 2005 ; Mo, 2010 ; Cheng et al, 2012 ; Liu, 2014 ; Zhuo et al, 2016 ; Xu et al, 2019 ; Wang, 2020b ; Wang et al, 2021b ; Liu and Yuan, 2021 ; Yang et al, 2021 ) had a therapy duration of <3 months ( p = 0.03, I 2 = 53%), eleven studies ( Xu et al, 2014 ; Luo and Liu, 2016 ; Feng et al, 2017 ; Liu, 2018 ; Song, 2018 ; Huang et al, 2019a ; Huang, 2019 ; Han, 2020 ; Liu, 2020 ; Ma and Zhou, 2020 ; Meng et al, 2020 ) had a therapy duration of 3 months ( p < 0.00001, I 2 = 88%), one study ( Huang et al, 2019b ) reported a therapy duration of 4 months, and three studies ( Jiang et al, 2018 ; Wang et al, 2018 ; Liu, 2019 ) had a therapy duration of 6 months ( p < 0.00001, I 2 = 93%), suggesting some heterogeneity. The random-effect model showed a significant beneficial effect of TCM adjuvant therapy on MMSE scores [MD = 2.55, 95% CI (1.99, 3.10), p < 0.00001; MD = 2.53, 95% CI (1.59, 3.47), p < 0.00001; MD = 2.91, 95% CI (1.26, 4.56), p = 0.0006; MD = 3.11, 95% CI (−0.04, 6.27), p = 0.05].…”

Section: Resultsmentioning

confidence: 99%

“…Subgroup analysis was carried out to examine differences in therapy duration. Ten studies (Liu and Liu, 2005;Mo, 2010;Cheng et al, 2012;Liu, 2014;Zhuo et al, 2016;Xu et al, 2019;Wang, 2020b;Wang et al, 2021b; Liu and (Xu et al, 2014;Luo and Liu, 2016;Feng et al, 2017;Liu, 2018;Song, 2018;Huang et al, 2019a;Huang, 2019;Han, 2020;Liu, 2020;Ma and Zhou, 2020;Meng et al, 2020) had a therapy duration of 3 months (p < 0.00001, I 2 = 88%), one study (Huang et al, 2019b) reported a therapy duration of 4 months, and three studies (Jiang et al, 2018;Wang et al, 2018;Liu, 2019) had a therapy duration of 6 months (p < 0.00001, I 2 = 93%), suggesting some heterogeneity.…”

Section: Mmsementioning

confidence: 99%

See 4 more Smart Citations

Traditional Chinese Medicine for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Background: Post-stroke cognitive impairment (PSCI) affects more than one-third of stroke patients, and causes much greater harm to long-term function than the initial brain damage. No conventional Western medications have shown convincing clinical effectiveness for treating PSCI. Research shows that Traditional Chinese medicine (TCM) can improve cognitive function in patients. However, the clinical efficacy and safety remain controversial. The aim of this study was to examine the effectiveness and harmful effects of TCMs in the treatment of PSCI.Method: We searched seven databases and two clinical registration websites for randomized controlled trials (RCTs). The revised Cochrane risk of bias tool (RoB 2.0) was used to evaluate the methodological quality and RevMan 5.4 was used for data analysis. This study has been submitted to PROSPERO with registration number is CRD42020149299.Results: We included 34 studies in this review. The results of this study showed that TCM adjuvant therapy improved scores on the MoCA [MD = 2.55, 95% CI (1.56, 3.53), p < 0.00001; MD = 3.07, 95% CI (1.98, 4.17), p < 0.00001 at treatment duration of <3 and 3 months, respectively], MMSE [MD = 2.55, 95% CI (1.99, 3.10), p < 0.00001; MD = 2.53, 95% CI (1.59, 3.47), p < 0.00001; MD = 2.91, 95% CI (1.26, 4.56), p = 0.0006; MD = 3.11, 95% CI (−0.04, 6.27), p = 0.05 at treatment duration of <3, 3, 4, and 6 months, respectively], and BI [MD = 7.34, 95% CI (3.83, 10.85), p < 0.0001; MD = 8.98, 95% CI (4.76, 13.21), p < 0.0001 at treatment duration of <3 and 3 months, respectively] and reduced scores on the ADL (MD = −8.64, 95% CI (−9.83, −7.45), p < 0.00001; MD = −2.00, 95% CI (−2.94, −1.06), p < 0.0001 at treatment duration of 3 and 4 months, respectively], NIHSS [MD = −2.48, 95% CI (−4.97, 0.00), p = 0.05; MD = −3.81, 95% CI (−6.21, −1.40), p = 0.002 at treatment duration of <3 and 3 months, respectively], and CSS [MD = −2.47, 95% CI (−3.49, −1.45), p < 0.00001 at a treatment duration of 3 months]. No serious adverse reactions were observed.Conclusion: Despite the significant positive results, the present evidence supports, to a limited extent because of the methodological flaws and herbal heterogeneity, that TCM adjuvant therapy can be used for patients with PSCI. While, further rigorous RCTs are warranted to confirm the efficacy and safety of TCM.Systematic Review Registration:https://www.crd.york.ac.uk/prospero, identifier CRD42020149299.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

“…Subgroup analysis was carried out to examine differences in therapy duration. Ten studies (Liu and Liu, 2005;Mo, 2010;Cheng et al, 2012;Liu, 2014;Zhuo et al, 2016;Xu et al, 2019;Wang, 2020b;Wang et al, 2021b; Liu and (Xu et al, 2014;Luo and Liu, 2016;Feng et al, 2017;Liu, 2018;Song, 2018;Huang et al, 2019a;Huang, 2019;Han, 2020;Liu, 2020;Ma and Zhou, 2020;Meng et al, 2020) had a therapy duration of 3 months (p < 0.00001, I 2 = 88%), one study (Huang et al, 2019b) reported a therapy duration of 4 months, and three studies (Jiang et al, 2018;Wang et al, 2018;Liu, 2019) had a therapy duration of 6 months (p < 0.00001, I 2 = 93%), suggesting some heterogeneity.…”

Section: Mmsementioning

confidence: 99%

See 3 more Smart Citations

Traditional Chinese Medicine for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

Comparative efficacy and safety of multiple acupuncture therapies for post stroke cognitive impairment: a network meta-analysis of randomized controlled trials

et al. 2023

View full text Add to dashboard Cite

BackgroundAcupuncture therapy has been widely used to treat post-stroke cognitive impairment (PSCI). However, acupuncture therapy includes multiple forms. Which acupuncture therapy provides the best treatment outcome for patients with PSCI remains controversial.ObjectiveWe aimed to compare and evaluate the efficacy and safety of different acupuncture-related therapies for PSCI in an attempt to identify the best acupuncture therapies that can improve cognitive function and self-care in daily life for patients with PSCI, and bring new insights to clinical practice.MethodWe searched eight databases including PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, China Biomedical Literature Database (CBM), China Science and Technology Journal (VIP) database, China National Knowledge Infrastructure (CNKI) database, and Wan fang database to find randomized controlled trials (RCTs) of acupuncture-related therapies for PSCI from the inception of the database to January 2023. Two researchers independently assessed the risk of bias in the included studies and extracted the study data. Pairwise meta-analyzes for direct comparisons were performed using Rev. Man 5.4 software. Bayesian network meta-analysis (NMA) was performed using STATA 17.0 and R4.2.4 software. The quality of evidence from the included studies was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. Adverse effects (AEs) associated with acupuncture therapy were collected by reading the full text of the included studies to assess the safety of acupuncture therapy.ResultsA total of 62 RCTs (3 three-arm trials and 59 two-arm trials) involving 5,073 participants were included in this study. In the paired meta-analysis, most acupuncture-related therapies had a positive effect on cognitive function and self-care of daily living in patients with PSCI compared with cognitive training. Bayesian NMA results suggested that ophthalmic acupuncture plus cognitive training (79.7%) was the best acupuncture therapy for improving MMSE scores, with scalp acupuncture plus cognitive training ranking as the second (73.7%). The MoCA results suggested that warm acupuncture plus cognitive training (86.5%) was the best acupuncture therapy. In terms of improvement in daily living self-care, scalp acupuncture plus body acupuncture (87.5%) was the best acupuncture therapy for improving MBI scores. The most common minor AEs included subcutaneous hematoma, dizziness, sleepiness, and pallor.ConclusionAccording to our Bayesian NMA results, ophthalmic acupuncture plus cognitive training and warm acupuncture plus cognitive training were the most effective acupuncture treatments for improving cognitive function, while scalp acupuncture plus body acupuncture was the best acupuncture treatment for improving the performance of self-care in daily life in patients with PSCI. No serious adverse effects were found in the included studies, and acupuncture treatment appears to be safe and reliable. However, due to the low methodological quality of the included studies, our findings need to be treated with caution. High-quality studies are urgently needed to validate our findings.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/#recordDetails, identifier: CRD42022378353.

show abstract

Effect of Baisuifang Granule on cognitive malfunction after cerebral infarction

Abstract: Baisuifang Granule is an effective Chinese medicine for treating cognitive malfunction after cerebral infarction.

Cited by 2 publications

References 1 publication

Traditional Chinese Medicine for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

Traditional Chinese Medicine for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

Comparative efficacy and safety of multiple acupuncture therapies for post stroke cognitive impairment: a network meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About